Abstract
Thrombolytic therapy in acute thrombotic diseases was introduced in France in the late 1960s. It has been applied in acute myocardial infarction since 1972 and was reported in 1975 [1]. The beneficial effect was appreciated in randomized studies on clinical follow-up dealing with cardiac death, rhythm disturbances and heart failure during the acute phase of myocardial infarction and on recurrent myocardial infarction, aneurysms and cardiac or noncardiac deaths in long-term follow-up [2].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Brochier M, Raynaud R, Planiol T et al. (1975) Le traitement par l’urokinase des infarctus du myocarde et syndromes de menace. Etude randomisée de 120 cas. Arch Mal Coeur 68: 563–569
Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ et al. (1985) Intravenous and intracor- onary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 6: 556–585
Rentrop KP, Blanke H, Karsch HR, Kaiser H, Kostering H, Leitz K (1981) Selective intra- coronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63: 307–310
European Cooperative Study Group (1981) Streptokinase in acute myocardial infarction: extended report of the European Cooperative Trial. In: Verstraete M, van de Loo J, Jesdinsky H J (eds) Streptokinase in acute myocardial infarction. Acta Med Scand [Suppl] 648: 7–57
Brochier M, Charbonnier B, Raynaud P, Quilliet L (1987) Residual stenosis in evolving myocardial infarction. A randomized study of APSAC versus streptokinase. J Am Coll Cardiol 9: 231 (Abstract)
Villemant D, Barriot P, Riou B, Bodenan P, Brunet F, Noto R, Monsallier JF (1987) Achievement of thrombolysis at home in cases of acute myocardial infarction. Lancet 1: 228–229
Castaigne AD, Duval AM, Dubois-Rande JL, Herve C, Jan F, Louvard (1987) Prehospital administration of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Drugs 33 (Suppl 3): 231–234
Groupe Epidémiologie et Prévention de la Société Française de Cardiologie. Fréquence et conditions d’hospitalisation des infarctus du myocarde récents en France: l’enquête nationale ENIM84. Arch Mal Coeur (in press)
Report from the European Cooperative Study Group of Recombinant Tissue-Type Plasminogen Activator (1985) Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1: 842–847
Verstraete M, Brower RW, Collen D et al. (1985) Double blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 2: 965–969
Brochier ML, Quilliet L, Kulbertus H et al. (1987) Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction: preliminary data from a randomised multicentre study. Drugs 33 (Suppl 3): 140–145
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Brochier, M.L., Charbonnier, B. (1989). Status of Thrombolytic Therapy in Acute Myocardial Infarction in France. In: Schmutzler, H., Rutsch, W., Dougherty, F.C. (eds) Limitation of Infarct Size. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73585-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-73585-1_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19148-3
Online ISBN: 978-3-642-73585-1
eBook Packages: Springer Book Archive